Tempest Achieves Key Manufacturing Milestone for Lead CAR-T Therapy TPST-2003, Paving Way for Pivotal Study
Summary
Tempest Therapeutics announced a key manufacturing milestone for its lead dual-targeting CAR-T therapy, TPST-2003, for relapsed/refractory multiple myeloma. The company's manufacturing partner received the lentiviral vector, a critical component for TPST-2003 production. This achievement is crucial as it enables Tempest to proceed with manufacturing activities required for a potentially registrational study later this year. This progress is particularly significant for the micro-cap company, which recently disclosed a 'going concern' warning in its 10-K but highlighted a strategic pivot into CAR-T cell therapy with strong early data for TPST-2003. Investors will now monitor for the initiation of the registrational study and the presentation of updated clinical results later this year.
At the time of this announcement, TPST was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.4M. The 52-week trading range was $1.50 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.